e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

20th September 2019 by Louise Hudman

e-learning | Ertugliflozin in type 2 diabetes and the other SGLT-2 inhibitors

This is a new guideline from NICE giving advice on ertugliflozin, published in April 2019. I am also doing a quick reminder about the other SGLT-2 inhibitors.

What is ertugliflozin?

It is another sodium-glucose co-transporter 2 (SGLT-2) inhibitor, like canagliflozin, dapagliflozin and empagliflozin.

It is thought to be as effective as the other SGLT-2 inhibitors, but it is cheaper.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

Related content

"I have found LocumDeck to be the most helpful and invaluable resource for keeping bookings and accounts. I want to thank you for the wonderful service you provide. Many thanks once again for all the NASGP provides, and particularly for use of the excellent resource LocumDeck has proved to be – something I have recommended to many colleagues who have taken a step to locum work."

Dr Ruth Snowball

Dr Ruth Snowball

See the full list of features within our NASGP membership plans

Membership